Nanomedicine for the prevention, treatment and imaging of atherosclerosis.

Nanomedicine for the prevention, treatment and imaging of atherosclerosis.

Pokaż inne wersje (2)

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in developed countries, with an increasing prevalence due to an aging population. The pathology underpinning CVD is atherosclerosis, a chronic inflammatory state involving the arterial wall. Accumulation of low density lipo...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Psarros, C, Lee, R, Margaritis, M, Antoniades, C
Format:	Journal article
Język:	English
Wydane:	2012

Podobne zapisy

Nanomedicine for the prevention, treatment and imaging of atherosclerosis
od: Psarros, C, i wsp.
Wydane: (2012)

Nanomedicine for the prevention, treatment and imaging of atherosclerosis.
od: Psarros, C, i wsp.
Wydane: (2012)

Nanomedicine for Diagnosis and Treatment of Atherosclerosis
od: Jingyun Cheng, i wsp.
Wydane: (2023-12-01)

Construction of dual nanomedicines for the imaging and alleviation of atherosclerosis
od: Shuihua Zhang, i wsp.
Wydane: (2020-01-01)

The role of adiponectin at different stages of atherosclerosis in heart failure: associations with myocardial redox state
od: Antonopoulos, A, i wsp.
Wydane: (2010)

Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis
od: Yongfang Lin, i wsp.
Wydane: (2024-06-01)

Nanoparticles: a promising therapeutic approach in atherosclerosis.
od: Antoniades, C, i wsp.
Wydane: (2010)

Biomimetic nanomedicines for precise atherosclerosis theranostics
od: Ying Tao, i wsp.
Wydane: (2023-11-01)

Editorial: Advances on targeted nanomedicines for atherosclerosis
od: Qinggong Han, i wsp.
Wydane: (2022-10-01)

Novel therapeutic strategies targeting vascular redox in human atherosclerosis.
od: Antonopoulos, A, i wsp.
Wydane: (2009)

Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis
od: Ping Ping Hu, i wsp.
Wydane: (2022-09-01)

Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications
od: Xue Li, i wsp.
Wydane: (2022-10-01)

Statin treatment improves vascular redox state through a tetrahydrobiopterin-mediated re-coupling of endothelial nitric oxide synthase, in human atherosclerosis
od: Antoniades, C, i wsp.
Wydane: (2011)

Multifunctional phototheranostic nanomedicine for cancer imaging and treatment
od: D. Gao, i wsp.
Wydane: (2020-01-01)

Precision nanomedicine in atherosclerosis therapy: how far are we from reality?
od: Yee Shan Wong, i wsp.
Wydane: (2019-01-01)

Precision nanomedicine in atherosclerosis therapy: how far are we from reality?
od: Yee Shan Wong, i wsp.

Interrelationships between vascular superoxide and adiponectin biosynthesis in perivascular adipose tissue in human atherosclerosis
od: Bakogiannis, C, i wsp.
Wydane: (2010)

Shedding new light on atherosclerosis therapeutics: Nanomedicines targeting atherosclerotic immune microenvironment
od: Zhiyue Wang, i wsp.
Wydane: (2024-12-01)

Nanomedicine for renal cell carcinoma: imaging, treatment and beyond
od: Ruolin Wu, i wsp.
Wydane: (2023-01-01)

Adiponectin as a regulator of vascular redox state in human atherosclerosis
od: Margaritis, M
Wydane: (2016)

L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis?
od: Siasos, G, i wsp.
Wydane: (2007)

A NOVEL CROSS-TALK BETWEEN PERIVASCULAR ADIPOSE TISSUE AND THE ARTERIAL WALL CONTROLS REDOX STATE IN HUMAN ATHEROSCLEROSIS
od: Margaritis, M, i wsp.
Wydane: (2013)

A novel cross-talk between perivascular adipose tissue and the arterial wall controls redox state in human atherosclerosis
od: Margaritis, M, i wsp.
Wydane: (2013)

Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition
od: Akoumianakis, I, i wsp.
Wydane: (2020)

Macrophage-targeting Antisenescence nanomedicine enables in-Situ NO induction for Gaseous and antioxidative atherosclerosis intervention
od: Yuanyuan Peng, i wsp.
Wydane: (2025-06-01)

Insulin Treatment Induces Oxidative Stress in the Vascular Wall of Patients With Atherosclerosis Independently of Diabetes or Systemic Insulin Resistance: The Protective Role of DPP-IV Inhibition
od: Akoumianakis, I, i wsp.
Wydane: (2018)

Statins in coronary artery bypass grafting surgery: lipid lowering and beyond.
od: Margaritis, M, i wsp.
Wydane: (2012)

Macrophage membrane-functionalized manganese dioxide nanomedicine for synergistic treatment of atherosclerosis by mitigating inflammatory storms and promoting cholesterol efflux
od: Sijin Chen, i wsp.
Wydane: (2024-10-01)

Biomarkers of premature atherosclerosis.
od: Kampoli, A, i wsp.
Wydane: (2009)

An immunoregulator nanomedicine approach for the treatment of tuberculosis
od: Luona Yang, i wsp.
Wydane: (2023-05-01)

Atorvastatin rapidly reduces myocardial superoxide and peroxynitrite generation in human atherosclerosis, by suppressing NADPH-oxidase activity independently of LDL lowering
od: Antoniades, C, i wsp.
Wydane: (2011)

Challenges to Safe Nanomedicine Treatment
od: Chunhua Yang, i wsp.
Wydane: (2023-03-01)

Nanomedicine: Engineering of a tri-imageable nanoparticle for diagnostics
od: Bumb, A, i wsp.
Wydane: (2009)

The role of perivascular fat in the diagnosis and prognosis of atherosclerosis
od: Polkinghorne, M, i wsp.
Wydane: (2022)

Homocysteine lowering: any use in atherosclerosis?
od: Antoniades, C, i wsp.
Wydane: (2007)

Perivascular adipose tissue and coronary atherosclerosis
od: Mancio, J, i wsp.
Wydane: (2018)

State-of-the-art review article. Atherosclerosis affecting fat: What can we learn by imaging perivascular adipose tissue?
od: Antoniades, C, i wsp.
Wydane: (2019)

Nanomedicine Explored at Molecular Imaging Summit
od: Julie L. Sutcliffe PhD
Wydane: (2011-01-01)

The Role of Optical Imaging in Translational Nanomedicine
od: Evelien Hesemans, i wsp.
Wydane: (2022-08-01)

Advances in nanomedicines for lymphatic imaging and therapy
od: Pan He, i wsp.
Wydane: (2023-08-01)